Characterization of nine Pasteurella multocida isolates from avian cholera outbreaks in Indonesia.
Avian cholera outbreaks have been identified in Indonesia in recent years. Despite vaccination programs, outbreaks continue to occur. To date, there has been a lack of information on the characteristics of Pasteurella multocida isolates involved in these outbreaks. Hence, the objective of this study was to characterize Indonesian P. multocida isolates in poultry. During 1998-99, 20 field outbreaks were reported in Indonesia. Nine isolates of P. multocida were recovered from these field outbreaks. The isolates were compared with four vaccine strains that were used in Indonesia and designated PM-V1, PM-V2, PM-V3, and PM-V4. The isolates were characterized by biotype, capsular type, somatic serotype, restriction endonuclease analysis, plasmid presence, and antimicrobial susceptibility patterns. Of the nine Indonesian isolates, three were of capsular type A (A:1,3,13; A:1,3; and A:8). One isolate was of type B:2,3 and one isolate was of capsular type F. For three isolates, the capsular serogroup could not be identified. Plasmids the size of 2.3 kbp were present in three of the field isolates and two of the vaccine strains. One plasmid less than 2 kbp was isolated from the vaccine strain PM-V4. Eight distinct DNA profiles were obtained from digestion with the restriction endonuclease EcoRI, and seven distinct DNA profiles were obtained from digestion with the restriction endonuclease HindIII. All of the isolates were resistant to lincomycin and sulfadiazine and were susceptible to ampicillin and trimethoprim. Of the nine isolates, seven (78%) were susceptible to doxycycline and gentamicin and six (67%) were susceptible to enrofloxacin.
Jonas
M
M
Department of Veterinary Preventive Medicine, The Ohio State University, Columbus 43210, USA.
Morishita
T Y
TY
Angrick
E J
EJ
Jahja
J
J
D000667:Ampicillin / Q000494:pharmacology; D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology; D002645:Chickens; D002771:Cholera / Q000453:epidemiology / Q000662:veterinary*; D015246:Deoxyribonuclease EcoRI / Q000378:metabolism; D015247:Deoxyribonuclease HindIII / Q000378:metabolism; D004196:Disease Outbreaks / Q000662:veterinary*; D004318:Doxycycline / Q000494:pharmacology; D000077422:Enrofloxacin; D024841:Fluoroquinolones; D005839:Gentamicins / Q000494:pharmacology; D007214:Indonesia / Q000453:epidemiology; D008034:Lincomycin / Q000494:pharmacology; D008826:Microbial Sensitivity Tests / Q000662:veterinary; D010326:Pasteurella Infections / Q000453:epidemiology / Q000662:veterinary*; D016979:Pasteurella multocida / Q000145:classification* / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification; D011201:Poultry Diseases / Q000453:epidemiology* / Q000382:microbiology; D015363:Quinolones / Q000494:pharmacology; D012703:Serotyping / Q000662:veterinary; D013411:Sulfadiazine / Q000494:pharmacology; D014295:Trimethoprim / Q000494:pharmacology
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D005839:Gentamicins; D015363:Quinolones; D013411:Sulfadiazine; D000077422:Enrofloxacin; D000667:Ampicillin; D014295:Trimethoprim; D008034:Lincomycin; D015246:Deoxyribonuclease EcoRI; D015247:Deoxyribonuclease HindIII; D004318:Doxycycline